DIABETOLOGY

Bydureon BCise( exenatide)

AstraZeneca’s Bydureon BCise( exenatide extended- release) is a formerly-daily treatment approved for type 2 diabetes. Bydureon BCise is a long- acting form of exenatide, the same active component set up in Byetta, but Byetta is given doubly-a-day rather of formerly-a-week. The Bydureon BCise injection is used with diet and exercise in people on one or further type 2 diabetes drugs to ameliorate blood sugar control. It isn't used as a first- line agent. Bydureon is a glucagon- suchlike peptide 1( GLP- 1) agonist, or incretin unoriginal, that binds to GLP- 1 receptors to help the pancreas produce further insulin in response to an increase in blood sugar. It's in the same class of medicine as Trulicity, Victoza, Rybelsus and Ozempic, among others.

Humalog( insulin lispro) Insulin is a hormone that works to lower situations of blood glucose( blood sugar) and is set up either naturally in the body or man- made and given by injection or inhalation. The development of life- saving insulin for people with diabetes is one of the top medical improvements in the history of drug. Jardiance( empagliflozin) Jardiance( empagliflozin), from Boehringer Ingelheim and Eli Lilly, is classified as a sodium glucoseco-transporter-2( SGLT2) asset and was firstly approved in 2014 to ameliorate blood sugar control( HbA1c) in grown-ups with type 2 diabetes alongside diet and exercise.

Jardiance is also approved to lower the threat of cardiovascular death in adult cases with type 2 diabetes and heart complaint. Lantus( insulin glargine) While short- acting insulins like Humalog are used at mealtimes, long- acting rudimentary insulins work to keep the blood sugar situations indeed throughout the day.

Lantus( insulin glargine), from Sanofi, is used to treat grown-ups with type 2 diabetes and grown-ups and children 6 times and aged with type 1 diabetes. Soliqua100/33( insulin glargine and lixisenatide) Sanofi’s Soliqua100/33 injection( insulin glargine and lixisenatide) is a combination of insulin glargine 100 Units/ mL and lixisenatide 33 mcg/ mL, a glucagon- suchlike peptide- 1( GLP- 1) agonist. The two medicines combined now mean one injection for the case with type 2 diabetes, rather of two. That is a big enhancement.

Toujeo( insulin glargine) Long- acting insulin injections help cases with diabetes control their blood sugar situations over a 24- hour period. Sanofi’s Toujeo( insulin glargine) is the same active component that is in Lantus. Toujeo is a formerly- daily, long- acting rudimentary insulin for grown-ups with type 1 or type 2 diabetes.

Trulicity( dulaglutide) Trulicity( dulaglutide) is a glucagon- suchlike peptide- 1( GLP- 1) receptor agonist for the treatment of type 2 diabetes. It's in the same class of medicine as Bydureon BCise, Victoza, Rybelsus and Ozempic, among others. Victoza( liraglutide) Victoza( liraglutide) from Novo Nordisk is also a glucagon- suchlike peptide- 1( GLP- 1) receptor agonist( incretin unoriginal) indicated to ameliorate glycemic control in grown-ups with type 2 diabetes mellitus. It's in the same class of medicine as Trulicity, Ozempic, Rybelsus and Bydureon BCise. Ozempic & Rybelsus Ozempic( semaglutide) is a glucagon- suchlike peptide- 1( GLP- 1) analog from Novo Nordisk. It's used in cases with type 2 diabetes as an adjunct to diet and exercise to ameliorate blood sugar control, and also to to reduce the threat of events like a heart attack, stroke or death in grown-ups with established heart complaint